- Home
- ANVS vs VTGN Comparison
ANVS vs VTGN Comparison
Compare ANVS & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | VTGN |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 21.8M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANVS | VTGN |
|---|---|---|
| Price | $1.99 | $0.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $13.50 | $0.90 |
| AVG Volume (30 Days) | 359.7K | ★ 471.6K |
| Earning Date | 03-16-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $0.43 |
| 52 Week High | $5.50 | $5.14 |
Technical Indicators
Market Signals| Indicator | ANVS | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 40.05 |
| Support Level | $1.97 | $0.50 |
| Resistance Level | $2.99 | $0.60 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 1.89 | 6.32 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.